Sumit Sehgal, MD
Cardiovascular Disease (Cardiology) · Gilroy
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 3 carriers
- Offices
- 5
Offices
5 locations · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
18 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sehgal’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$96,794
Medicare paid this office $96,794 for 763 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 270 | $15,973 | $58 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 45 | $12,456 | $277 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 92 | $8,654 | $94 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 45 | $8,454 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $6,974 | $152 |
See all 23 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 270 | $15,973 | $58 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 45 | $12,456 | $277 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 92 | $8,654 | $94 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 45 | $8,454 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $6,974 | $152 |
| Short return visit (20+ min) | 157 | $6,739 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $4,819 | $69 |
| Return visit (30+ min) | 63 | $4,521 | $71 |
| Provision of test materials and equipment for home inr monitoring of patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; includes: provision of materials for use in the | 57 | $2,979 | $23 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 51 | $2,228 | $44 |
| New patient visit (45+ min) | 25 | $2,045 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $1,889 | $105 |
| Injection, regadenoson, 0.1 mg | 37 | $1,640 | None |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,631 | $109 |
| Ultrasound of heart with probe in esophagus, with report | 20 | $1,615 | $81 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 128 | $852 | $6 |
| Ultrasound of heart, follow-up | 13 | $567 | $44 |
| Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | 59 | $406 | $3 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 11 | $154 | $14 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 12 | $142 | $12 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 12 | $132 | $11 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 16 | $81 | $5 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $30 | $2 |
Who their Medicare patients are
763 Original Medicare patients in 2024. Average age 77 · Under 65 6% · 85 and older 22% · Women 50% · Also on Medicaid 23% · Health risk score 1.75. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 48% · Atrial fibrillation 47% · Heart failure 44% · Diabetes 40% · Chronic kidney disease 39% · Depression 23% · COPD 22% · Cancer 16% · Stroke 14% · Dementia 12%.
The office billed $715,742, Medicare allowed $144,878 and paid $96,794; for 2,597 services of 44 kinds; $9,804 of it was for drugs given in the office and $86,990 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 763 | 2,597 | 77 | 1.75 | $715,742 | $96,794 |
| 2023 | 1,534 | 6,880 | 77 | 1.34 | $1,207,409 | $319,926 |
| 2022 | 1,786 | 6,309 | 77 | 1.42 | $1,284,481 | $346,314 |
| 2021 | 1,943 | 6,639 | 77 | 1.47 | $1,360,052 | $418,945 |
| 2020 | 1,799 | 5,617 | 77 | 1.61 | $1,066,343 | $320,646 |
| 2019 | 1,047 | 2,739 | 77 | 1.63 | $466,353 | $149,434 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 35 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 161 | $51,137 | $318 |
| Short return visit (20+ min) | 607 | $44,133 | $59 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 312 | $42,730 | $137 |
| Return visit (30+ min) | 328 | $32,701 | $88 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 161 | $30,968 | $96 |
| Provision of test materials and equipment for home inr monitoring of patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; includes: provision of materials for use in the | 75 | $25,705 | $44 |
| Injection, regadenoson, 0.1 mg | 119 | $17,647 | None |
| New patient visit (45+ min) | 130 | $14,445 | $111 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 183 | $8,323 | $45 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 122 | $6,346 | $52 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 441 | $4,466 | $9 |
| Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | 75 | $3,451 | $6 |
| Ultrasound of heart with probe in esophagus, with report | 39 | $3,357 | $80 |
| Injection, perflutren lipid microspheres, per ml | 44 | $3,136 | $35 |
| Ultrasound of heart, follow-up | 27 | $1,960 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,590 | $59 |
| External shock to heart to regulate heart beat | 19 | $1,516 | $80 |
| New patient visit (30+ min) | 20 | $1,454 | $73 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $1,138 | $15 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 19 | $927 | $49 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 34 | $599 | $18 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 88 | $539 | $6 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 68 | $499 | $7 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 27 | $496 | $18 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 27 | $461 | $16 |
| Programming of dual lead pacemaker system | 13 | $413 | $32 |
| Blood test, clotting time | 22 | $365 | $4 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 26 | $347 | $13 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 15 | $292 | $19 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 20 | $291 | $15 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 35 | $272 | $8 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 39 | $223 | $5 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 39 | $98 | $2 |
| Heart rhythm recording of continous external ekg over 8-15 days | 13 | $97 | $7 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 13 | $73 | $6 |
2022: 36 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 173 | $57,213 | $331 |
| Return visit (30+ min) | 395 | $43,383 | $90 |
| Short return visit (20+ min) | 535 | $42,021 | $63 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 173 | $37,151 | $107 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 245 | $35,207 | $142 |
| Injection, regadenoson, 0.1 mg | 122 | $21,615 | None |
| New patient visit (45+ min) | 183 | $20,291 | $111 |
| Provision of test materials and equipment for home inr monitoring of patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; includes: provision of materials for use in the | 51 | $14,551 | $32 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 393 | $11,265 | $20 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 506 | $10,986 | $15 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 183 | $8,471 | $46 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 118 | $4,523 | $26 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 83 | $4,257 | $51 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 398 | $4,120 | $9 |
| Programming of dual lead pacemaker system | 50 | $3,189 | $58 |
| Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | 51 | $2,619 | $6 |
| Ultrasound of heart with probe in esophagus, with report | 25 | $2,064 | $83 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 27 | $1,507 | $33 |
| Ultrasound of heart, follow-up | 19 | $1,413 | $71 |
| Injection, perflutren lipid microspheres, per ml | 18 | $1,230 | $34 |
| External shock to heart to regulate heart beat | 15 | $1,220 | $81 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 24 | $1,154 | $48 |
| Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 11 | $1,142 | $104 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 27 | $912 | $20 |
| New patient visit (30+ min) | 11 | $833 | $76 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 25 | $483 | $19 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $479 | $17 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 19 | $363 | $18 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 19 | $338 | $17 |
| Electrocardiogram (ecg) 2-day continuous with report | 11 | $305 | $28 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 14 | $284 | $19 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 16 | $214 | $13 |
| Blood test, clotting time | 25 | $173 | $4 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 31 | $156 | $5 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 25 | $137 | $5 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 25 | $60 | $2 |
2021: 36 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 245 | $85,734 | $350 |
| Return visit (30+ min) | 549 | $65,637 | $89 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 253 | $53,885 | $108 |
| Injection, regadenoson, 0.1 mg | 179 | $31,726 | None |
| Short return visit (20+ min) | 392 | $30,447 | $64 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 179 | $26,757 | $149 |
| New patient visit (45+ min) | 236 | $25,803 | $109 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 568 | $13,097 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 262 | $12,204 | $46 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 417 | $11,897 | $21 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 124 | $6,671 | $54 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 155 | $5,640 | $26 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 25 | $5,279 | $96 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 409 | $4,890 | $10 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $4,843 | $54 |
| Programming of dual lead pacemaker system | 88 | $4,605 | $48 |
| External shock to heart to regulate heart beat | 31 | $2,828 | $83 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,703 | $142 |
| Ultrasound of heart with probe in esophagus, with report | 20 | $1,680 | $84 |
| Ultrasound of heart, follow-up | 21 | $1,362 | $65 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 21 | $1,104 | $53 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 26 | $1,076 | $19 |
| Programming of dual lead implantable defibrillator system | 16 | $1,013 | $63 |
| Programming of multiple lead implantable defibrillator system | 13 | $925 | $71 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 29 | $886 | $17 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 41 | $830 | $19 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 118 | $798 | $6 |
| Programming of single lead pacemaker system | 16 | $780 | $46 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 18 | $320 | $18 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 18 | $299 | $17 |
| Blood test, clotting time | 33 | $296 | $4 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 12 | $277 | $20 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 19 | $262 | $14 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 16 | $233 | $15 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 20 | $111 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 20 | $49 | $2 |
2020: 34 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 181 | $63,338 | $350 |
| Return visit (30+ min) | 397 | $43,157 | $79 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 182 | $39,257 | $108 |
| Injection, regadenoson, 0.1 mg | 143 | $25,187 | None |
| Short return visit (20+ min) | 351 | $24,666 | $50 |
| New patient visit (45+ min) | 179 | $18,996 | $106 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 122 | $17,474 | $143 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 182 | $10,803 | $57 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 511 | $10,381 | $16 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 380 | $9,961 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 195 | $9,273 | $47 |
| Programming of dual lead pacemaker system | 100 | $5,589 | $51 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 339 | $5,150 | $11 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 30 | $4,859 | $99 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 135 | $4,516 | $26 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $3,556 | $56 |
| External shock to heart to regulate heart beat | 27 | $2,702 | $84 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 38 | $2,319 | $61 |
| Ultrasound of heart with probe in esophagus, with report | 20 | $1,899 | $86 |
| Programming of dual lead implantable defibrillator system | 23 | $1,792 | $69 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 28 | $924 | $21 |
| Programming of multiple lead implantable defibrillator system | 11 | $837 | $70 |
| Ultrasound of heart, follow-up | 11 | $739 | $67 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 100 | $651 | $6 |
| New patient visit (30+ min) | 11 | $646 | $59 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 85 | $589 | $6 |
| Programming of single lead pacemaker system | 11 | $493 | $45 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 23 | $455 | $20 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 26 | $437 | $17 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 23 | $324 | $12 |
| Electrocardiogram (ecg) 2-day continuous with report | 12 | $317 | $26 |
| Blood test, clotting time | 30 | $178 | $4 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 26 | $166 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 26 | $73 | $3 |
2019: 24 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 85 | $29,814 | $351 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 86 | $18,367 | $107 |
| Return visit (30+ min) | 156 | $14,293 | $81 |
| Short return visit (20+ min) | 192 | $13,538 | $55 |
| Injection, regadenoson, 0.1 mg | 69 | $12,126 | None |
| New patient visit (45+ min) | 97 | $11,351 | $117 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 319 | $6,239 | $18 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 238 | $5,885 | $23 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 98 | $5,521 | $56 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 38 | $5,224 | $137 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 93 | $4,332 | $47 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 220 | $3,178 | $12 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 84 | $3,037 | $33 |
| New patient visit (30+ min) | 31 | $2,322 | $75 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $1,809 | $55 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,676 | $152 |
| Programming of dual lead pacemaker system | 29 | $1,506 | $47 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 11 | $1,505 | $94 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 123 | $943 | $6 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 12 | $720 | $60 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $352 | $17 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 51 | $336 | $6 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 11 | $303 | $19 |
| Blood test, clotting time | 25 | $141 | $4 |
Medicaid work
$6,666 in 2024
Medicaid paid $6,666 for 341 billed services this clinician did in 2024, up to 84 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 326 | $6,229 |
| Short return visit (20+ min) | 15 | $437 |
| 2024 | 341 | 2 | 84 | $6,666 |
| 2023 | 219 | 4 | 25 | $13,638 |
| 2022 | 348 | 6 | 26 | $14,973 |
| 2021 | 870 | 6 | 43 | $40,437 |
| 2020 | 556 | 6 | 56 | $22,067 |
| 2019 | 168 | 4 | 57 | $2,812 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 75 | $8,876 |
| Short return visit (20+ min) | 118 | $4,097 |
| Return visit (30+ min) | 13 | $411 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 13 | $255 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 52 | $4,764 |
| Short return visit (20+ min) | 117 | $3,422 |
| New patient visit (45+ min) | 32 | $2,894 |
| Return visit (30+ min) | 57 | $2,230 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 76 | $1,423 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, leadless pacemaker system, or implantable defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 14 | $240 |
2021
| Return visit (30+ min) | 336 | $14,938 |
| New patient visit (45+ min) | 123 | $11,160 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 40 | $5,729 |
| Short return visit (20+ min) | 161 | $4,421 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 177 | $3,779 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, leadless pacemaker system, or implantable defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 33 | $410 |
2020
| Return visit (30+ min) | 127 | $5,952 |
| Short return visit (20+ min) | 162 | $5,823 |
| New patient visit (45+ min) | 43 | $4,458 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 31 | $3,068 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 132 | $2,306 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 61 | $459 |
2019
| Short return visit (20+ min) | 29 | $1,097 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 65 | $1,033 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 62 | $528 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, leadless pacemaker system, or implantable defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 12 | $154 |
Drugs they prescribed that Part D paid
$415,929
Pharmacies billed $415,929 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,578) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
3,078 generic and 500 brand-name prescriptions · $415,929 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 280 | $235,746 | $842 |
| Xarelto | 70 | $69,083 | $987 |
| Entresto | 19 | $23,313 | $1,227 |
| Brilinta | 24 | $11,222 | $468 |
| Praluent | 16 | $7,936 | $496 |
See all 42 drugs
| Eliquis | 280 | $235,746 | $842 |
| Xarelto | 70 | $69,083 | $987 |
| Entresto | 19 | $23,313 | $1,227 |
| Brilinta | 24 | $11,222 | $468 |
| Praluent | 16 | $7,936 | $496 |
| Metoprolol | 407 | $5,902 | $15 |
| Potassium Chloride | 148 | $2,409 | $16 |
| Ranolazine Er | 19 | $2,220 | $117 |
| Atorvastatin | 305 | $2,058 | $7 |
| Ezetimibe | 47 | $1,455 | $31 |
| Sotalol | 110 | $1,441 | $13 |
| Valsartan | 84 | $1,299 | $15 |
| Amiodarone | 77 | $1,232 | $16 |
| Midodrine | 18 | $1,229 | $68 |
| Diltiazem 24hr Er (Cd) | 80 | $1,186 | $15 |
| Losartan | 141 | $954 | $7 |
| Rosuvastatin | 106 | $937 | $9 |
| Hydralazine | 70 | $917 | $13 |
| Dofetilide | 14 | $906 | $65 |
| Metoprolol | 144 | $777 | $5 |
| Clopidogrel | 105 | $734 | $7 |
| Verapamil Er | 32 | $702 | $22 |
| Carvedilol | 132 | $660 | $5 |
| Amlodipine Besylate | 139 | $624 | $4 |
| Isosorbide Mononitrate Er | 59 | $604 | $10 |
| Bumetanide | 27 | $574 | $21 |
| Diltiazem 24hr Er | 16 | $538 | $34 |
| Spironolactone | 112 | $537 | $5 |
| Furosemide | 145 | $503 | $3 |
| Lisinopril | 101 | $488 | $5 |
| Torsemide | 36 | $414 | $11 |
| Warfarin | 45 | $410 | $9 |
| Flecainide Acetate | 13 | $365 | $28 |
| Pravastatin | 21 | $334 | $16 |
| Nitroglycerin | 29 | $272 | $9 |
| Hydrochlorothiazide | 71 | $247 | $3 |
| Simvastatin | 25 | $160 | $6 |
| Telmisartan | 13 | $134 | $10 |
| Atenolol | 20 | $129 | $6 |
| Triamterene-Hydrochlorothiazid | 13 | $127 | $10 |
| Doxazosin Mesylate | 11 | $120 | $11 |
| Chlorthalidone | 11 | $80 | $7 |
Year by year
| 2024 | 3,578 | 868 | 0% (0) | 14% | $415,929 |
| 2023 | 6,795 | 1,152 | 0% (0) | 10% | $649,133 |
| 2022 | 6,690 | 1,156 | 0% (0) | 11% | $582,383 |
| 2021 | 6,678 | 1,150 | 0% (0) | 13% | $469,366 |
| 2020 | 5,239 | 836 | 0% (0) | 10% | $280,189 |
| 2019 | 1,138 | 373 | 0% (0) | 10% | $42,950 |
| 2017 | 43 | None | 0% (0) | 0% | $431 |
| 2016 | 43 | None | 0% (0) | None | $918 |
| 2015 | 11 | None | None | 0% | $56 |
| 2013 | 11 | None | None | 0% | $98 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 55 drugs
| Eliquis | 424 | $358,586 | $846 |
| Xarelto | 80 | $89,218 | $1,115 |
| Praluent | 49 | $30,539 | $623 |
| Brilinta | 21 | $16,356 | $779 |
| Entresto | 13 | $14,115 | $1,086 |
| Metoprolol | 740 | $12,961 | $18 |
| Potassium Chloride | 366 | $9,978 | $27 |
| Atorvastatin | 662 | $7,601 | $11 |
| Ezetimibe | 92 | $5,258 | $57 |
| Bumetanide | 93 | $4,572 | $49 |
| Ranolazine Er | 34 | $4,285 | $126 |
| Dofetilide | 16 | $3,827 | $239 |
| Amiodarone | 169 | $3,662 | $22 |
| Valsartan | 140 | $3,585 | $26 |
| Diltiazem 24hr Er (Cd) | 132 | $3,261 | $25 |
| Losartan | 284 | $2,987 | $11 |
| Rosuvastatin | 182 | $2,950 | $16 |
| Clopidogrel | 165 | $2,739 | $17 |
| Carvedilol | 324 | $2,389 | $7 |
| Sotalol | 161 | $2,293 | $14 |
| Hydralazine | 139 | $2,163 | $16 |
| Warfarin | 135 | $1,837 | $14 |
| Furosemide | 283 | $1,746 | $6 |
| Flecainide Acetate | 30 | $1,724 | $57 |
| Verapamil Er | 66 | $1,630 | $25 |
| Metoprolol | 243 | $1,600 | $7 |
| Spironolactone | 214 | $1,580 | $7 |
| Amlodipine Besylate | 244 | $1,513 | $6 |
| Bisoprolol | 27 | $1,458 | $54 |
| Lisinopril | 212 | $1,400 | $7 |
| Valsartan-Hydrochlorothiazide | 31 | $1,355 | $44 |
| Clonidine | 11 | $1,342 | $122 |
| Pravastatin | 71 | $1,126 | $16 |
| Isosorbide Mononitrate Er | 99 | $1,121 | $11 |
| Midodrine | 19 | $1,021 | $54 |
| Nitroglycerin | 58 | $956 | $16 |
| Propranolol | 24 | $861 | $36 |
| Simvastatin | 82 | $728 | $9 |
| Diltiazem 24hr Er | 21 | $679 | $32 |
| Hydrochlorothiazide | 135 | $587 | $4 |
| Losartan-Hydrochlorothiazide | 19 | $578 | $30 |
| Torsemide | 33 | $547 | $17 |
| Potassium Citrate Er | 12 | $449 | $37 |
| Fenofibrate | 29 | $446 | $15 |
| Enalapril Maleate | 21 | $432 | $21 |
| Doxazosin Mesylate | 24 | $424 | $18 |
| Olmesartan Medoxomil | 13 | $405 | $31 |
| Triamterene-Hydrochlorothiazid | 39 | $384 | $10 |
| Telmisartan | 17 | $241 | $14 |
| Atenolol | 28 | $193 | $7 |
| Clonidine | 12 | $185 | $15 |
| Verapamil | 21 | $180 | $9 |
| Chlorthalidone | 21 | $158 | $8 |
| Benazepril | 13 | $132 | $10 |
| Irbesartan | 23 | $109 | $5 |
2022: 51 drugs
| Eliquis | 457 | $365,695 | $800 |
| Xarelto | 42 | $39,217 | $934 |
| Praluent | 32 | $21,615 | $675 |
| Entresto | 12 | $16,099 | $1,342 |
| Brilinta | 21 | $13,041 | $621 |
| Metoprolol | 757 | $12,748 | $17 |
| Potassium Chloride | 324 | $10,927 | $34 |
| Repatha Sureclick | 13 | $8,207 | $631 |
| Ezetimibe | 99 | $7,132 | $72 |
| Atorvastatin | 661 | $6,080 | $9 |
| Amiodarone | 157 | $5,323 | $34 |
| Bumetanide | 108 | $5,059 | $47 |
| Valsartan | 125 | $4,136 | $33 |
| Diltiazem 24hr Er (Cd) | 131 | $3,702 | $28 |
| Losartan | 315 | $2,914 | $9 |
| Clopidogrel | 161 | $2,621 | $16 |
| Carvedilol | 346 | $2,516 | $7 |
| Sotalol | 159 | $2,470 | $16 |
| Ranolazine Er | 32 | $2,203 | $69 |
| Rosuvastatin | 129 | $1,741 | $13 |
| Flecainide Acetate | 28 | $1,736 | $62 |
| Hydralazine | 110 | $1,474 | $13 |
| Spironolactone | 203 | $1,413 | $7 |
| Metoprolol | 265 | $1,372 | $5 |
| Furosemide | 322 | $1,317 | $4 |
| Isosorbide Mononitrate Er | 119 | $1,299 | $11 |
| Amlodipine Besylate | 287 | $1,105 | $4 |
| Lisinopril | 217 | $1,086 | $5 |
| Warfarin | 142 | $1,062 | $7 |
| Diltiazem 24hr Er | 29 | $912 | $31 |
| Pravastatin | 58 | $890 | $15 |
| Nitroglycerin | 48 | $877 | $18 |
| Valsartan-Hydrochlorothiazide | 37 | $809 | $22 |
| Verapamil Er | 43 | $721 | $17 |
| Simvastatin | 91 | $662 | $7 |
| Propranolol | 23 | $651 | $28 |
| Bisoprolol | 19 | $617 | $32 |
| Hydrochlorothiazide | 130 | $559 | $4 |
| Olmesartan Medoxomil | 11 | $530 | $48 |
| Fenofibrate | 19 | $450 | $24 |
| Doxazosin Mesylate | 14 | $364 | $26 |
| Enalapril Maleate | 14 | $350 | $25 |
| Torsemide | 11 | $252 | $23 |
| Fenofibrate | 13 | $247 | $19 |
| Irbesartan | 16 | $193 | $12 |
| Losartan-Hydrochlorothiazide | 13 | $160 | $12 |
| Triamterene-Hydrochlorothiazid | 25 | $153 | $6 |
| Chlorthalidone | 11 | $145 | $13 |
| Atenolol | 28 | $127 | $5 |
| Clonidine | 11 | $124 | $11 |
| Verapamil | 13 | $100 | $8 |
2021: 49 drugs
| Eliquis | 420 | $284,105 | $676 |
| Xarelto | 64 | $39,271 | $614 |
| Entresto | 21 | $19,021 | $906 |
| Praluent | 33 | $16,635 | $504 |
| Metoprolol | 651 | $11,319 | $17 |
| Bumetanide | 93 | $6,579 | $71 |
| Atorvastatin | 623 | $6,455 | $10 |
| Ezetimibe | 111 | $5,556 | $50 |
| Potassium Chloride | 258 | $4,988 | $19 |
| Losartan | 427 | $3,879 | $9 |
| Ranolazine Er | 61 | $3,707 | $61 |
| Diltiazem 24hr Er (Cd) | 146 | $3,676 | $25 |
| Rosuvastatin | 127 | $3,333 | $26 |
| Amiodarone | 129 | $3,209 | $25 |
| Carvedilol | 427 | $2,982 | $7 |
| Clopidogrel | 209 | $2,192 | $10 |
| Sotalol | 148 | $1,999 | $14 |
| Metoprolol | 350 | $1,701 | $5 |
| Spironolactone | 240 | $1,665 | $7 |
| Flecainide Acetate | 35 | $1,555 | $44 |
| Hydralazine | 107 | $1,300 | $12 |
| Valsartan | 29 | $1,294 | $45 |
| Isosorbide Mononitrate Er | 134 | $1,221 | $9 |
| Furosemide | 374 | $1,197 | $3 |
| Lisinopril | 211 | $1,188 | $6 |
| Diltiazem 24hr Er | 43 | $1,000 | $23 |
| Midodrine | 20 | $960 | $48 |
| Warfarin | 107 | $942 | $9 |
| Hydrochlorothiazide | 180 | $856 | $5 |
| Amlodipine Besylate | 226 | $825 | $4 |
| Fenofibrate | 28 | $663 | $24 |
| Pravastatin | 51 | $654 | $13 |
| Propranolol | 28 | $613 | $22 |
| Enalapril Maleate | 17 | $511 | $30 |
| Cartia Xt | 11 | $467 | $42 |
| Nitroglycerin | 33 | $435 | $13 |
| Simvastatin | 65 | $413 | $6 |
| Bisoprolol | 14 | $355 | $25 |
| Digoxin | 11 | $342 | $31 |
| Olmesartan Medoxomil | 14 | $312 | $22 |
| Triamterene-Hydrochlorothiazid | 31 | $287 | $9 |
| Atenolol | 22 | $279 | $13 |
| Fenofibrate | 11 | $263 | $24 |
| Diltiazem | 20 | $206 | $10 |
| Irbesartan | 13 | $205 | $16 |
| Pantoprazole | 19 | $181 | $10 |
| Pacerone | 13 | $112 | $9 |
| Benazepril | 12 | $108 | $9 |
| Lisinopril-Hydrochlorothiazide | 12 | $28 | $2 |
2020: 48 drugs
| Eliquis | 232 | $136,691 | $589 |
| Xarelto | 43 | $24,431 | $568 |
| Praluent | 20 | $16,504 | $825 |
| Entresto | 21 | $15,838 | $754 |
| Pradaxa | 11 | $9,801 | $891 |
| Metoprolol | 524 | $7,821 | $15 |
| Potassium Chloride | 258 | $3,932 | $15 |
| Atorvastatin | 399 | $3,790 | $9 |
| Rosuvastatin | 183 | $3,492 | $19 |
| Bumetanide | 84 | $3,087 | $37 |
| Ezetimibe | 79 | $2,797 | $35 |
| Diltiazem 24hr Er (Cd) | 123 | $2,516 | $20 |
| Amiodarone | 71 | $2,229 | $31 |
| Carvedilol | 376 | $2,084 | $6 |
| Ranolazine Er | 30 | $2,004 | $67 |
| Losartan | 268 | $1,801 | $7 |
| Warfarin | 165 | $1,665 | $10 |
| Hydralazine | 121 | $1,655 | $14 |
| Clopidogrel | 189 | $1,328 | $7 |
| Isosorbide Mononitrate Er | 118 | $1,226 | $10 |
| Sotalol | 82 | $1,153 | $14 |
| Lisinopril | 240 | $1,080 | $5 |
| Metoprolol | 266 | $1,018 | $4 |
| Pravastatin | 47 | $1,017 | $22 |
| Midodrine | 18 | $989 | $55 |
| Spironolactone | 208 | $982 | $5 |
| Furosemide | 245 | $787 | $3 |
| Valsartan | 19 | $632 | $33 |
| Diltiazem 24hr Er | 28 | $625 | $22 |
| Amlodipine Besylate | 149 | $600 | $4 |
| Cartia Xt | 15 | $580 | $39 |
| Enalapril Maleate | 25 | $529 | $21 |
| Nitroglycerin | 37 | $502 | $14 |
| Bisoprolol | 13 | $490 | $38 |
| Hydrochlorothiazide | 93 | $457 | $5 |
| Digoxin | 15 | $445 | $30 |
| Valsartan-Hydrochlorothiazide | 11 | $440 | $40 |
| Fludrocortisone Acetate | 18 | $390 | $22 |
| Chlorthalidone | 21 | $346 | $16 |
| Propafenone | 13 | $317 | $24 |
| Atenolol | 33 | $206 | $6 |
| Simvastatin | 43 | $199 | $5 |
| Diltiazem | 16 | $187 | $12 |
| Triamterene-Hydrochlorothiazid | 16 | $186 | $12 |
| Trandolapril | 12 | $126 | $11 |
| Pantoprazole | 13 | $91 | $7 |
| Jantoven | 12 | $60 | $5 |
| Lisinopril-Hydrochlorothiazide | 11 | $39 | $4 |
2019: 24 drugs
| Eliquis | 35 | $16,825 | $481 |
| Rosuvastatin | 40 | $2,031 | $51 |
| Bumetanide | 29 | $1,458 | $50 |
| Potassium Chloride | 79 | $1,227 | $16 |
| Metoprolol | 78 | $1,167 | $15 |
| Atorvastatin | 100 | $954 | $10 |
| Amiodarone | 12 | $691 | $58 |
| Warfarin | 49 | $549 | $11 |
| Chlorthalidone | 20 | $449 | $22 |
| Hydralazine | 23 | $409 | $18 |
| Nitroglycerin | 20 | $375 | $19 |
| Carvedilol | 63 | $291 | $5 |
| Ezetimibe | 12 | $284 | $24 |
| Lisinopril | 74 | $276 | $4 |
| Pravastatin | 18 | $254 | $14 |
| Isosorbide Mononitrate Er | 21 | $251 | $12 |
| Diltiazem 24hr Er (Cd) | 18 | $218 | $12 |
| Clopidogrel | 38 | $217 | $6 |
| Spironolactone | 31 | $206 | $7 |
| Losartan | 48 | $203 | $4 |
| Metoprolol | 82 | $199 | $2 |
| Furosemide | 71 | $152 | $2 |
| Amlodipine Besylate | 32 | $131 | $4 |
| Simvastatin | 14 | $59 | $4 |
2017: 2 drugs
| Spironolactone | 14 | $106 | $8 |
| Carvedilol | 11 | $66 | $6 |
Money from drug and device companies
$62 in 2025
| 2025 | 2 | 2 | None | $62 |
| 2024 | 1 | 1 | None | $21 |
| 2023 | 2 | 2 | None | $25 |
| 2022 | 2 | 4 | None | $55 |
| 2021 | 2 | 2 | None | $25 |
| 2020 | 4 | 10 | None | $787 |
| 2019 | 5 | 6 | None | $371 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
See all 2 published payments
| Cleerly | Meals · 2025-10-22 | Cleerly Ischemia | $42 |
| Heartflow | Meals · 2025-10-21 | Ffrct | $20 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $21
| Amgen | Repatha | $21 | 1 payment
|
2023: $25
| E.R. Squibb & Sons L.L.C. | Camzyos | $20 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $5 | 1 payment
|
2022: $55
| Boston Scientific | Watchman Access System | $43 | 3 payments
|
| Novartis Pharmaceuticals | Leqvio | $12 | 1 payment
|
2021: $25
| Abbott Laboratories | Cardiomems Hf System | $22 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $4 | 1 payment
|
2020: $787
| Biotronik | None | $755 | 7 payments
|
| Boston Scientific | Watchman | $14 | 1 payment
|
| Novo Nordisk | None | $13 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $4 | 1 payment
|
2019: $371
| CVRx | Barostim Neo System | $125 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $81 | 2 payments
|
| Abbott Laboratories | Cardiomems Hf System | $69 | 1 payment
|
| Medtronic Vascular | Heartware Hvad | $55 | 1 payment
|
| Terumo Medical | Angioseal | $42 | 1 payment
|
Professional record
- NPI
- 1083956502
- Licence
- IA MD-45758
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Student in a training program (390200000X)
- Mailing address
- Po Box 9170, Des Moines, IA, 50306
- NPI first listed
- 2013-03-22
- NPI last updated
- 2019-11-05
This is when the NPI record was last certified, not a medical board exam.